Hepatitis-B reactivation during treatment with tumor necrosis factor-blocker adalimumab in a patient with psoriasis arthritis;Hepatitis-B-Reaktivierung unter TNF -α- Blocker- Therapie mit Adalimumab bei Psoriasis-Arthritis

Deutsche Medizinische Wochenschrift

Volumn 137, Issue 1-2, 2012, Pages 23-26

  Kouba, M ^a   Rudolph, S E ^a   Hrdlicka, P ^a   Zuber, M A ^a  

^a Department of Urology   (Germany)

Author keywords

adalimumab; hepatitis B infection; immunosuppression; psoriasis arthritis; reactivation; tumor necrosis factor

Indexed keywords

ADALIMUMAB; DIGITOXIN;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; HEPATITIS B; HUMAN; LIVER BIOPSY; MALE; MUSCLE HYPOTONIA; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; SEROLOGY; TACHYCARDIA; VIRUS REACTIVATION;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BIOPSY; DIAGNOSIS, DIFFERENTIAL; DRUG-INDUCED LIVER INJURY; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER; LIVER FAILURE; MALE; PSORIASIS; VIRUS ACTIVATION;

EID: 83755161557     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0031-1292885     Document Type: Article

References (16)

1. Cornberg M et al. Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virus-(HBV-) Infektion. Upgrade der Leitlinie, AWMF-Register-Nr.: 021/011. Z Gastroenterol: 2007; 45 1 50
2. European Association for the Study of the Liver EASL Clinical Practice Guidelines: Management of chronic hepatitis B. Journal of Hepatology: 2009; 50 227 242
3. Guidotti LG, Ishikawa T, Hobbs MV et al. Intracellula inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity: 1996; 4 25 36 (Pubitemid 26054933)
4. Hussain MJ, Lau JY, Williams R et al. Hepatic expression of tumor necrosis factor-alpha in chronic hepatitis B virus infection. J Clin Pathol: 1994; 47 1112 1115
5. Katsounas A et al. Therapie der chronischen Hepatitis B und C: Problempatienten. Gastroenterologe: 2006; 1 133 140
6. Li S, Kaur PP, Chan V et al. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin Rheumatol: 2009; 28 787 791
7. Manger B, Michels H, Nsslein HG et al. Therapie mit Tumornekrosefaktor hemmenden Wirkstoffen bei entzndlich-rheumatischen Erkrankungen. Z Rheumatologie: 2007; 66 72 75
8. Matsumoto T, Marusawa H, Dogaki M. Adalimumab-induced lethal hepatitis B virus reactivation in a HbsAG-negative patient with clinically resolved hepatitis B virus infection. Liver Int: 2010; 30 1241 1242
9. Ramos-Casals M. Are TNF blockers safe for patients with hepatitis B virus infection. Nat Rev Rheumatol: 2010; 6 618 620
10. Rantala M, van de Laar MJ. Surveillance and epidemiology of hepatitis B and C in Europe A review. Euro Surveill: 2008; 13 18880
11. RKI Epidemiologisches Bulletin Nr. 20, Virushepatitis B, C und D. Situationsbericht Deutschland: 2008
12. Roux CH, Brocq O, Breuil V et al. Safety of anti-TNF-alpha therapy in rheumatoid arthritis an spondylarthropathies with concurrent B or C chronic hepatitis. Rheumathology: 2006; 45 1294 1297 (Pubitemid 44542073)
13. Sheran N et al. Increased production of tumor necrosis factor alpha in chronic hepatitis B virus infection. J Hepatol: 1991; 12 241 245
14. Su F, Schneider RJ. Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha. Proc Natl Acad ci USA: 1997; 94 8744 8749 (Pubitemid 27335110)
15. Vassilopoulos D et al. Long-term safety of anti-TNF treatement in Patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis: 2010; 69 1352 1355
16. Verheist X, Orlent H, Colle I et al. Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B. Eur J Gastroenterol Hepatol: 2010; 22 494 499